Finance

Lists
Outlook: 5.9% bullish·52.9% bearish
Go to analysis
XRAY:NASDAQ
DENTSPLY SIRONA Inc
$9.70
+1.68%
(+0.16) 1D
$9.67
-0.31% (-0.030)
After hours
Closed: Nov 10, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XRAY...
Open
$9.35
High
$9.81
Low
$9.24
Mkt. cap
1.92B
Avg. vol.
5.03M
Volume
6.02M
52-wk high
$14.76
52-wk low
$8.14
EPS
-$0.61
Beta
0.87
Shares outstanding
198.15M
No. of employees
14K
Open
$9.35
High
$9.81
Low
$9.24
Mkt. cap
1.92B
Avg. vol.
5.03M
Volume
6.02M
52-wk high
$14.76
52-wk low
$8.14
EPS
-$0.61
Beta
0.87
Shares outstanding
198.15M
No. of employees
14K
News stories
From web sources and news partners
Profile
Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million. As an equipment maker, it designs and manufactures laboratory and specialty products relating to dental supplies. With regard to consumable products, it specializes in anesthetics, plaque and gum disease prevention and tooth polishers. It also designs and constructs artificial teeth. It has also been cited as a key player in the future intra-oral flat panel sensor market. Because of the income disparity between wealthy and developing nations, the variety of products in demand differs from region to region. On August 28, 2022, Dentsply Sirona announced the appointment of Simon D. Campion, formerly Executive Vice President and President of the Interventional segment for BD, as President and Chief Executive Officer and a member of the board. In 2018 a Netherlands-based certification company awarded Dentsply the “Top Employer” certification. Wikipedia
About DENTSPLY SIRONA Inc
CEODaniel T. Scavilla
Employees14K
Founded2016
Headquarters-
SectorHealth Care
IndustryMedical device
Websitedentsplysirona.com
Analyst ratings
Based on 11 analysts giving stock ratings to XRAY in the past 3 months
Hold
Buy
2
Hold
8
Sell
1
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for XRAY in the last 3 months.
Highest
Current $9.70
$14.00 (+44.33%)
Average
$10.64 (+9.69%)
Lowest
$8.00 (-17.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Petusky
Barrington
Buy
Maintained
$11.00
+13.4%
11/09/2026
Michael Sarcone
Jefferies
Hold
Maintained
$10.00
+3.1%
11/06/2026
Lilia-Celine (Lily) Lozada
J.P. Morgan
Hold
Maintained
$10.00
+3.1%
11/06/2026
Allen Lutz
Bank of America Securities
Buy
Reiterated
$14.00
+44.3%
11/06/2026
Erin Wright
Morgan Stanley
Hold
Reiterated
$11.00
+13.4%
11/06/2026
Steven Valiquette
Mizuho Securities
Hold
Maintained
$11.00
+13.4%
11/06/2026
Jeff Johnson
Robert W. Baird
Hold
Maintained
$9.00
-7.2%
11/06/2026
Glen Santangelo
Barclays
Sell
Maintained
$11.00
+13.4%
11/06/2026
Vik Chopra
BMO Capital
Hold
Maintained
$8.00
-17.5%
11/06/2026
Michael Cherny
Leerink Partners
Hold
Maintained
$10.00
+3.1%
10/14/2026
Jason Bednar
Piper Sandler
Hold
Reiterated
$12.00
+23.7%
10/09/2026
Jonathan Block
Stifel Nicolaus
Hold
Maintained
$14.00
+44.3%
08/07/2026
Elizabeth Anderson CFA
Evercore ISI
Hold
Maintained
$14.00
+44.3%
08/07/2026
Brandon Vazquez
William Blair
Hold
Maintained
-
-
08/07/2026
David Saxon
Needham
Hold
Maintained
-
-
08/07/2026
Unknown Analyst
BMO Capital
Hold
Initiated
$12.00
+23.7%
07/09/2026
Kevin Caliendo
UBS
Buy
Maintained
$17.00
+75.3%
05/07/2026
Daniel Grosslight
Citi
Sell
Maintained
$10.50
+8.2%
05/06/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$13.00
+34%
02/27/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.29 / $0.31
-6.24%miss
Revenue / Est. (USD)
836.00M / 861.65M
-2.98%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
961.00M
880.00M
898.00M
836.00M
Cost of goods sold
518.00M
453.00M
405.00M
393.00M
Cost of revenue
518.00M
453.00M
405.00M
393.00M
Research and development expenses
40.00M
44.00M
45.00M
42.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
386.00M
353.00M
365.00M
364.00M
Operating expense
426.00M
397.00M
410.00M
406.00M
Total operating expenses
944.00M
850.00M
815.00M
799.00M
Operating income
17.00M
30.00M
83.00M
37.00M
Other non operating income
-2.00M
6.00M
-
-
EBT including unusual items
-147.00M
-42.00M
72.00M
26.00M
EBT excluding unusual items
12.00M
25.00M
74.00M
27.00M
Income tax expense
-2.00M
-32.00M
36.00M
29.00M
Effective tax rate
1.36%
76.19%
50.00%
111.54%
Other operating expenses
-
-
-
-
Net income
-146.00M
-10.00M
37.00M
-2.00M
Net profit margin
-15.19%
-1.14%
4.12%
-0.24%
Earnings per share
0.27
0.27
0.52
0.29
Interest and investment income
4.00M
-
4.00M
2.00M
Interest expense
-26.00M
-24.00M
-26.00M
-27.00M
Net interest expenses
-22.00M
-24.00M
-22.00M
-25.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
110.00M
109.00M
168.00M
119.00M
Gain or loss from assets sale
-
-6.00M
-
-1.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps